Artivion, Inc. (NYSE:AORT) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. cut its holdings in shares of Artivion, Inc. (NYSE:AORT) by 1.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 105,769 shares of the company’s stock after selling 1,430 shares during the quarter. Victory Capital Management Inc. owned 0.25% of Artivion worth $3,024,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in AORT. Lord Abbett & CO. LLC acquired a new stake in Artivion during the 3rd quarter worth approximately $5,798,000. Tidal Investments LLC lifted its holdings in Artivion by 602.2% during the 3rd quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock worth $4,179,000 after buying an additional 134,642 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after buying an additional 125,668 shares in the last quarter. Sio Capital Management LLC acquired a new stake in Artivion during the 3rd quarter worth approximately $3,226,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Artivion by 394.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock valued at $2,606,000 after purchasing an additional 78,120 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Artivion

In other Artivion news, insider John E. Davis sold 15,100 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $356,511.00. Following the transaction, the insider now directly owns 208,778 shares of the company’s stock, valued at approximately $4,929,248.58. This trade represents a 6.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jean F. Holloway sold 5,335 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $145,698.85. Following the transaction, the senior vice president now directly owns 149,799 shares in the company, valued at $4,091,010.69. The trade was a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,799 shares of company stock valued at $2,356,223 in the last ninety days. Insiders own 8.10% of the company’s stock.

Artivion Trading Up 3.1 %

NYSE AORT opened at $24.15 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The firm’s fifty day moving average price is $28.66 and its 200 day moving average price is $27.74. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1,207.25 and a beta of 1.79. Artivion, Inc. has a 12 month low of $19.36 and a 12 month high of $32.33.

Artivion (NYSE:AORT) last posted its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The company had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on AORT shares. JMP Securities restated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Stifel Nicolaus reduced their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Finally, Needham & Company LLC reduced their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.